These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 20979551)

  • 1. 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome.
    Wirtz PW; Titulaer MJ; Gerven JM; Verschuuren JJ
    Expert Rev Clin Immunol; 2010 Nov; 6(6):867-74. PubMed ID: 20979551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment.
    Quartel A; Turbeville S; Lounsbury D
    Curr Med Res Opin; 2010 Jun; 26(6):1363-75. PubMed ID: 20377318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome.
    McEvoy KM; Windebank AJ; Daube JR; Low PA
    N Engl J Med; 1989 Dec; 321(23):1567-71. PubMed ID: 2555713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS.
    Oh SJ; Claussen GG; Hatanaka Y; Morgan MB
    Muscle Nerve; 2009 Nov; 40(5):795-800. PubMed ID: 19722254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment in Lambert-Eaton myasthenic syndrome.
    Maddison P
    Ann N Y Acad Sci; 2012 Dec; 1275():78-84. PubMed ID: 23278581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palliative care for a patient with Lambert-Eaton myasthenic syndrome: role of 3,4-diaminopyridine.
    Chan KY; Chang RS; Lau VW; Chan ML; Lai T
    Ann Palliat Med; 2016 Oct; 5(4):311-314. PubMed ID: 27506750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome.
    Molgó J; Guglielmi JM
    Pflugers Arch; 1996; 431(6 Suppl 2):R295-6. PubMed ID: 8739381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome.
    Lundh H; Nilsson O; Rosén I; Johansson S
    Acta Neurol Scand; 1993 Aug; 88(2):136-40. PubMed ID: 8213058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.
    Wirtz PW; Verschuuren JJ; van Dijk JG; de Kam ML; Schoemaker RC; van Hasselt JG; Titulaer MJ; Tjaden UR; den Hartigh J; van Gerven JM
    Clin Pharmacol Ther; 2009 Jul; 86(1):44-8. PubMed ID: 19357643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment for Lambert-Eaton myasthenic syndrome.
    Maddison P; Newsom-Davis J
    Cochrane Database Syst Rev; 2003; (2):CD003279. PubMed ID: 12804456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-term treatment of Lambert-Eaton syndrome by 3, 4 diaminopyridine].
    Jost WH; Mielke U; Forrett-Kaminsky MC; Schimrigk K
    Rev Neurol (Paris); 1992; 148(12):776-9. PubMed ID: 1303573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term observation of incremental response and antibodies to voltage-gated calcium channels in patients with Lambert-Eaton myasthenic syndrome: two case reports.
    Schneider I; Kornhuber ME; Hanisch F
    J Med Case Rep; 2015 Mar; 9():59. PubMed ID: 25885033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of 3,4-diaminopyridine on the time course of decay of compound muscle action potential augmentation in the Lambert-Eaton myasthenic syndrome.
    Maddison P; Newsom-Davis J; Mills KR
    Muscle Nerve; 1998 Sep; 21(9):1196-8. PubMed ID: 9703446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine.
    Lindquist S; Stangel M
    Neuropsychiatr Dis Treat; 2011; 7():341-9. PubMed ID: 21822385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies.
    Titulaer MJ; Lang B; Verschuuren JJ
    Lancet Neurol; 2011 Dec; 10(12):1098-107. PubMed ID: 22094130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment for Lambert-Eaton myasthenic syndrome.
    Keogh M; Sedehizadeh S; Maddison P
    Cochrane Database Syst Rev; 2011 Feb; 2011(2):CD003279. PubMed ID: 21328260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Lambert-Eaton myasthenic syndrome (LEMS)].
    Suzuki S
    Brain Nerve; 2010 Apr; 62(4):419-26. PubMed ID: 20420183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lambert-Eaton myasthenic syndrome: search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis.
    Takamori M
    J Neuroimmunol; 2008 Sep; 201-202():145-52. PubMed ID: 18653248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amifampridine to treat Lambert-Eaton myasthenic syndrome.
    Oh SJ
    Drugs Today (Barc); 2020 Oct; 56(10):623-641. PubMed ID: 33185628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials.
    Zhang N; Hong D; Ouyang T; Meng W; Huang J; Li M; Hong T
    BMC Neurol; 2021 Sep; 21(1):371. PubMed ID: 34563155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.